The "Geroscience hypothesis" suggests that age-related diseases can be prevented or delayed by targeting common aging mechanisms. Among these mechanisms, the important role of sirtuins and NAD in regulating the aging process has been recognized.
It has been reported that increasing intracellular NAD can improve glucose and lipid metabolism, protect the heart from ischemic damage, and promote liver regeneration. Therefore, the use of NAD precursors such as nicotinamide, NMN, and NR to increase NAD levels is being explored as a strategy for the prevention and age-related diseases.
Figure 1NMN's pathway of action.
In 2023, the clinical trial of a special polycrystalline form of NMN, MIB-626, will be launched, and this revolutionary breakthrough has aroused widespread attention and expectations in the field of anti-aging.
Research published in the internationally renowned scientific journal The Journals of Gerontology: Series A by a team from MetroBiotech and Harvard Medical School shows that:The safety and tolerability of MIB-626 orally 1000 mg orally 1-2 times daily in the elderly is good, and with increasing doses, blood NAD+ levels and their metabolome are also improved to varying degrees. On top of that, the study didn't find any serious ***
Figure 2MIB-626 is an oral formulation of a microcrystalline unique NMN polymorph.
The study used a top-evidence, randomized controlled double-blind approach in which 32 participants aged 55-80 years were overweight or obese and divided into three groups. Of these, a group of 12 people was given 1000 mg of MIB-626 once daily over 14 days;Another group of 12 people took 1000 mg twice daily;The remaining participants were given placebo. Finally, blood tests and urine tests are performed, and the relevant data results are counted.
In the blood of **, the researchers found a clear difference between the three groups of subjects. Subjects taking MIB-626 had a significant increase in blood NMN concentrations compared to the treatment group. Specifically, when subjects took 1000 mg of MIB-626 once a day, its Cmax (reflecting the highest drug concentration in the body) and AUC (reflecting the total amount absorbed and bioavailable after the drug) were obtained27 times and 17 times。When subjects took 1000 mg of MIB-626 twice a day, these two indicators were separatedRaised to 45 times and 37 times。With the increase of the dose, the increase in NMN concentration is also more significant.
Figure 3Circulating concentrations of NAD and NMN and NAD metabolome in each group on days 1 and 14.
Under urine testing, the researchers found that the concentration of NMN in the urine did not differ significantly between the ** groups after the creatinine level was normalized. This indicates that the clearance rate of oral NMN in urine is very low, and the drug will not be excreted in the urine in the form of NMN.
And on days 8 and 14, the urine concentrations of NAM and 2-PY-NAM in the subjects taking NMN** were higher than those in the placebo groupThis may mean that NMN is converted into NAD+ in the body and absorbed and utilized.
Figure 4**Group primary NAD metabolite urine concentrations normalized to urine creatinine.
Overall, the results of this study demonstrate the great potential of NMN to increase NAD+ levels and improve metabolismBy supplementing with MIB-626, we have the potential to reverse this process, improve the body's metabolic health, and prevent or delay age-related diseases
Although this study is a qualitative leap forward in NMN, more research is needed to further understand the mechanism of action and long-term effects of MIB-626. and conducting clinical trials in a broader population to see if it is safe and effective in humans.
References: 1]Yoshino J, Mills KF, Yoon MJ, Imai S nicotinamide mononucleotide, a key nad(+)intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. cell metab. 2011;14(4):528–536.
2]pencina km, l**u s, dos santos m, beleva ym, cheng m, livingston d, bhasin s. mib-626, an oral formulation of a microcrystalline unique polymorph of β-nicotinamide mononucleotide, increases circulating nicotinamide adenine dinucleotide and its metabolome in middle-aged and older adults. j gerontol a biol sci med sci. 2023 jan 26;78(1):90-96.
The content of this article is ** from academic journals, and the relevant information is for sharing and learning only, and does not represent any medical advice. If there is any infringement, please write to the author of this article to delete, and the views in this article do not represent the position of Bangtai Biotech.